Prudential Financial Inc. reduced its position in shares of Charles River Laboratories International Inc. (NYSE:CRL) by 1.2% during the second quarter, according to its most recent disclosure with the SEC. The firm owned 350,929 shares of the company’s stock after selling 4,370 shares during the period. Prudential Financial Inc. owned approximately 0.74% of Charles River Laboratories International worth $28,931,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of CRL. Massmutual Trust Co. FSB ADV boosted its stake in shares of Charles River Laboratories International by 4.4% in the first quarter. Massmutual Trust Co. FSB ADV now owns 2,769 shares of the company’s stock worth $210,000 after buying an additional 117 shares during the period. LaSalle Street Capital Management LLC acquired a new stake in shares of Charles River Laboratories International during the second quarter worth approximately $215,000. Calvert Investment Management Inc. acquired a new stake in shares of Charles River Laboratories International during the second quarter worth approximately $223,000. Charter Trust Co. acquired a new stake in shares of Charles River Laboratories International during the second quarter worth approximately $224,000. Finally, Bogle Investment Management L P DE acquired a new stake in shares of Charles River Laboratories International during the first quarter worth approximately $249,000. Institutional investors and hedge funds own 96.19% of the company’s stock.

Shares of Charles River Laboratories International Inc. (NYSE:CRL) traded up 1.37% during mid-day trading on Thursday, hitting $82.84. 63,448 shares of the stock traded hands. Charles River Laboratories International Inc. has a one year low of $59.99 and a one year high of $89.18. The company has a market cap of $3.92 billion, a P/E ratio of 27.99 and a beta of 1.21. The stock has a 50 day moving average price of $82.71 and a 200-day moving average price of $81.92.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, August 3rd. The company reported $1.20 earnings per share for the quarter, beating the consensus estimate of $1.10 by $0.10. Charles River Laboratories International had a net margin of 9.49% and a return on equity of 25.18%. The firm earned $434.10 million during the quarter, compared to the consensus estimate of $425.05 million. During the same quarter in the previous year, the company posted $0.96 EPS. The firm’s revenue for the quarter was up 27.8% on a year-over-year basis. On average, analysts forecast that Charles River Laboratories International Inc. will post $4.45 earnings per share for the current fiscal year.

A number of brokerages have recently commented on CRL. Zacks Investment Research cut shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Friday, July 22nd. Credit Suisse Group AG began coverage on shares of Charles River Laboratories International in a research report on Monday, June 20th. They issued a “neutral” rating and a $84.00 target price for the company. Evercore ISI reiterated a “hold” rating and issued a $91.50 target price (up from $83.50) on shares of Charles River Laboratories International in a research report on Thursday, August 4th. Citigroup Inc. increased their target price on shares of Charles River Laboratories International from $85.00 to $90.00 and gave the company a “neutral” rating in a research report on Thursday, August 4th. Finally, Jefferies Group upped their price objective on shares of Charles River Laboratories International from $94.00 to $100.00 and gave the company a “buy” rating in a report on Thursday, August 4th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and five have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $86.21.

In related news, Director George Massaro sold 3,740 shares of the business’s stock in a transaction dated Friday, July 1st. The shares were sold at an average price of $83.09, for a total value of $310,756.60. Following the completion of the transaction, the director now owns 18,935 shares of the company’s stock, valued at approximately $1,573,309.15. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Chairman James C. Foster sold 18,351 shares of the business’s stock in a transaction dated Friday, August 5th. The shares were sold at an average price of $85.63, for a total transaction of $1,571,396.13. Following the completion of the transaction, the chairman now directly owns 383,283 shares of the company’s stock, valued at approximately $32,820,523.29. The disclosure for this sale can be found here. 2.30% of the stock is currently owned by corporate insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a full service, early-stage contract research company. The Company is engaged in the business of providing the research models required in research and development of new drugs, devices and therapies. The Company operates through three segments: Research Models and Services (RMS), which consists of Research Models and Research Model Services; Discovery and Safety Assessment (DSA), which offers discovery and safety assessment services, both regulated and non-regulated, in which it includes both in vivo and in vitro studies, and Manufacturing Support (Manufacturing), which includes Microbial Solutions, Biologics Testing Solutions and Avian Vaccine Services.

5 Day Chart for NYSE:CRL

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.